# Minoru Fukuda

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 62 papers | 584 citations | 11 h-index | 21 g-index |
| 69 ext. papers | 690 ext. citations | 3 avg, IF | 2.77 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 62 | Community-acquired pneumonia in Japan: a prospective ambulatory and hospitalized patient study. *Journal of Medical Microbiology*, **2005**, 54, 395-400 | 3.2 | 72 |
| 61 | Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. *Japanese Journal of Cancer Research*, **1995**, 86, 1198-202 | | 71 |
| 60 | Autotransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocyte colony-stimulating factor in childhood neuroblastoma and non-Hodgkin© lymphoma. *British Journal of Haematology*, **1992**, 80, 327-31 | 4.5 | 47 |
| 59 | IgM neutralizing antibody responses to human herpesvirus-6 in patients with exanthem subitum or organ transplantation. *Microbiology and Immunology*, **1992**, 36, 495-506 | 2.7 | 46 |
| 58 | Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. *Journal of Thoracic Oncology*, **2010**, 5, 1404-9 | 8.9 | 42 |
| 57 | Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. *Journal of Thoracic Oncology*, **2011**, 6, 121-7 | 8.9 | 23 |
| 56 | Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2004**, 54, 573-7 | 3.5 | 23 |
| 55 | Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. *Journal of Thoracic Oncology*, **2019**, 14, 2071-2083 | 8.9 | 18 |
| 54 | Bronchoscopic therapy for mucosa-associated lymphoid tissue lymphoma of the trachea. *Internal Medicine*, **1999**, 38, 276-8 | 1.1 | 13 |
| 53 | Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab. *Thoracic Cancer*, **2018**, 9, 193-196 | 3.2 | 13 |
| 52 | A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2006**, 58, 601-6 | 3.5 | 12 |
| 51 | A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. *Journal of Thoracic Oncology*, **2009**, 4, 741-5 | 8.9 | 11 |
| 50 | Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4. *Supportive Care in Cancer*, **2016**, 24, 615-619 | 3.9 | 10 |
| 49 | Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study. *Cancer*, **2007**, 110, 606-13 | 6.4 | 10 |
| 48 | High-risk populations for nasal carriage of methicillin-resistant Staphylococcus aureus. *Journal of Infection and Chemotherapy*, **2004**, 10, 189-91 | 2.2 | 10 |
| 47 | Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B). *Thoracic Cancer*, **2016**, 7, 467-72 | 3.2 | 10 |
| 46 | A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer. *Chemotherapy*, **2016**, 61, 93-8 | 3.2 | 9 |

| | | | |
|---|---|---|---|
| 45 | Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2012**, 70, 645-51 | 3.5 | 9 |
| 44 | Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. *Oncologist*, **2019**, 24, 593-e170 | 5.7 | 8 |
| 43 | Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction. *OncoTargets and Therapy*, **2017**, 10, 3211-3214 | 4.4 | 8 |
| 42 | Outbreak of Chlamydophila pneumoniae infection in long-term care facilities and an affiliated hospital. *Journal of Medical Microbiology*, **2005**, 54, 1243-1247 | 3.2 | 8 |
| 41 | Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer. *Cancer Management and Research*, **2010**, 2, 191-5 | 3.6 | 8 |
| 40 | Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701. *Japanese Journal of Clinical Oncology*, **2016**, 46, 741-7 | 2.8 | 7 |
| 39 | Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. *Thoracic Cancer*, **2018**, 9, 1522-1524 | 3.2 | 7 |
| 38 | Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201). *Lung Cancer*, **2019**, 132, 1-8 | 5.9 | 6 |
| 37 | Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. *Cancer Chemotherapy and Pharmacology*, **2016**, 78, 377-82 | 3.5 | 6 |
| 36 | Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer. *Thoracic Cancer*, **2018**, 9, 51-58 | 3.2 | 6 |
| 35 | Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer. *Thoracic Cancer*, **2019**, 10, 872-879 | 3.2 | 5 |
| 34 | Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer. *Thoracic Cancer*, **2017**, 8, 577-581 | 3.2 | 5 |
| 33 | A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L). *Journal of Thoracic Oncology*, **2021**, 16, 2121-2132 | 8.9 | 5 |
| 32 | A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L). *BMC Cancer*, **2020**, 20, 370 | 4.8 | 4 |
| 31 | A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2014**, 74, 497-502 | 3.5 | 4 |
| 30 | Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non-small-cell lung cancer. *Clinical Lung Cancer*, **2012**, 13, 347-51 | 4.9 | 4 |
| 29 | Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA. *Thoracic Cancer*, **2019**, 10, 452-458 | 3.2 | 4 |
| 28 | Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A). *Thoracic Cancer*, **2017**, 8, 40-45 | 3.2 | 3 |

| | | | |
|---|---|---|---|
| 27 | Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 3 |
| 26 | Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study. *Thoracic Cancer*, **2020**, 11, 1972-1978 | 3.2 | 3 |
| 25 | S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501. *Thoracic Cancer*, **2020**, 11, 693-696 | 3.2 | 3 |
| 24 | Both bronchial and vascular stenting followed by chemoradiotherapy for locally advanced non-small cell lung cancer. *Anticancer Research*, **2006**, 26, 565-7 | 2.3 | 3 |
| 23 | Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. *Thoracic Cancer*, **2019**, 10, 1764-1769 | 3.2 | 2 |
| 22 | Phase I/II study of amrubicin and nedaplatin in patients with untreated, advanced, non-small cell lung cancer. *Chemotherapy*, **2014**, 60, 180-4 | 3.2 | 2 |
| 21 | The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. *Cancer Medicine*, **2021**, 10, 3873-3885 | 4.8 | 2 |
| 20 | Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma: A case report. *Thoracic Cancer*, **2021**, 12, 1126-1130 | 3.2 | 2 |
| 19 | A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer. *Clinica Chimica Acta*, **2021**, 519, 51-59 | 6.2 | 2 |
| 18 | Paclitaxel and cisplatin with concurrent radiotherapy followed by surgery in locally advanced thymic carcinoma. *Anticancer Research*, **2007**, 27, 1601-4 | 2.3 | 2 |
| 17 | Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **2019**, 84, 1059-1064 | 3.5 | 1 |
| 16 | Clinical significance of humoral immunity against XAGE1 cancer-testis antigen in lung adenocarcinoma.. *Journal of Clinical Oncology*, **2018**, 36, 162-162 | 2.2 | 1 |
| 15 | Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study. *Thoracic Cancer*, **2020**, 11, 389-393 | 3.2 | 1 |
| 14 | Prediction of Anti-Cancer Drug-Induced Pneumonia in Lung Cancer Patients: Novel High-Resolution Computed Tomography Fibrosis Scoring. *Journal of Clinical Medicine*, **2020**, 9, | 5.1 | 1 |
| 13 | Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation. *Thoracic Cancer*, **2021**, 12, 272-276 | 3.2 | 1 |
| 12 | Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis. *Thoracic Cancer*, **2021**, 12, 2300-2306 | 3.2 | 1 |
| 11 | Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor. *Journal of Clinical Medicine*, **2021**, 10, | 5.1 | 1 |
| 10 | Pharmacokinetic parameters of gefitinib predicts its progression-free survival and adverse events.. *Journal of Clinical Oncology*, **2014**, 32, e19038-e19038 | 2.2 | 0 |

| | | | |
|---|---|---|---|
| 9 | A phase II study of osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer harboring EGFR mutations: The OCEAN study (LOGIK 1603/WJOG 9116L).. *Journal of Clinical Oncology*, **2020**, 38, 9597-9597 | 2.2 | 0 |
| 8 | Tracheal Paraganglioma: A Case report and Review of the Pertinent Literature. *Internal Medicine*, **2021**, 60, 2275-2283 | 1.1 | 0 |
| 7 | A Case of Advanced Thymic Carcinoma in Which Carboplatin and Nab-paclitaxel Were Significantly Effective After Progression on Lenvatinib. *Japanese Journal of Lung Cancer*, **2022**, 62, 115-120 | 0.1 | 0 |
| 6 | Serum NY-ESO-1 and XAGE1 antibodies as predictive biomarkers in anti-PD-1 therapy for non-small-cell lung cancer.. *Journal of Clinical Oncology*, **2019**, 37, 106-106 | 2.2 | |
| 5 | Carcinoembryonic antigen (CEA) as a candidate prognostic marker of nonmucinous pneumonic adenocarcinoma (P-ADC) of the lung. **2019**, 5, 28-28 | | |
| 4 | Prospective study for usefulness of circulating-free DNA on prediction of third generation EGFR tyrosine kinase inhibitors.. *Journal of Clinical Oncology*, **2020**, 38, e21510-e21510 | 2.2 | |
| 3 | Phase I study of amrubicin and cisplatin with concurrent thoracic radiotherapy (TRT) in limited-disease small cell lung cancer (LD-SCLC).. *Journal of Clinical Oncology*, **2017**, 35, e20023-e20023 | 2.2 | |
| 2 | Phase I/II study of amrubicin and nedaplatin in patients with untreated, advanced non-small cell lung cancer.. *Journal of Clinical Oncology*, **2012**, 30, 7569-7569 | 2.2 | |
| 1 | Which do patients prefer as a first-line therapy, EGFR-TKI or chemotherapy, if they have NSCLC harboring EGFR mutation? A Vignettes study (LOGIK0903).. *Journal of Clinical Oncology*, **2013**, 31, e19016-e19016 | 2.2 | |